FDA approval: Blinatumomab

Clinical Cancer Research

Volumn 21, Issue 18, 2015, Pages 4035-4039

  Przepiorka, Donna ^a   Ko, Chia Wen ^a   Deisseroth, Albert ^a   Yancey, Carolyn L ^a   Candau Chacon, Reyes ^a   Chiu, Haw Jyh ^a   Gehrke, Brenda J ^a   Gomez Broughton, Candace ^a   Kane, Robert C ^a   Kirshner, Susan ^a   Mehrotra, Nitin ^a   Ricks, Tiffany K ^a   Schmiel, Deborah ^a   Song, Pengfei ^a   Zhao, Ping ^a   Zhou, Qing ^a   Farrell, Ann T ^a   Pazdur, Richard ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BLINATUMOMAB; DEXAMETHASONE; IMMUNOGLOBULIN; INTERLEUKIN 10; ANTINEOPLASTIC AGENT; BISPECIFIC ANTIBODY; CD19 ANTIGEN; CD3 ANTIGEN; CYTOKINE;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; B CELL LEUKEMIA; BACKACHE; BONE PAIN; CANCER RECURRENCE; CANCER REGRESSION; CHILL; CLINICAL EFFECTIVENESS; CLINICAL TRIAL; CONSCIOUSNESS DISORDER; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; CYTOKINE RELEASE SYNDROME; DECREASED APPETITE; DIARRHEA; DIZZINESS; DRUG APPROVAL; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOOD AND DRUG ADMINISTRATION; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTRANSAMINASEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; IMMUNOGLOBULIN BLOOD LEVEL; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; MYALGIA; MYELOID LEUKEMIA; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OPEN STUDY; PRIORITY JOURNAL; RASH; REFRACTORY PERIOD; SEPSIS; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; TREMOR; VOMITING; ADOLESCENT; ANIMAL; CHEMISTRY; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METABOLISM; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MOUSE; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENT DISEASE; REMISSION; TREATMENT OUTCOME; UNITED STATES;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTIBODIES, BISPECIFIC; ANTIGENS, CD19; ANTIGENS, CD3; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; CYTOKINES; DISEASE-FREE SURVIVAL; DRUG APPROVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MICE; MIDDLE AGED; NEOPLASM, RESIDUAL; PRECURSOR B-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; REMISSION INDUCTION; TREATMENT OUTCOME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84942855711     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0612     Document Type: Article

References (19)

1. O'Brien S., Thomas D, Ravandi F., Faderl S, Cortes J, Borthakur G., et al. Outcome of adults with acute lymphocytic leukemia after second salvage therapy. Cancer 2008; 113: 3186-91.
2. Kantarjian H, Thomas D, Ravandi F., Faderl S, Jabbour E, Garcia-Manero G, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer 2010; 116: 5568-74.
3. Full prescribing information for Marqibo® (vinCRIStine sulfate LIPOSOME injection) for intravenous infusion [PDF on the Internet]. South San Francisco (CA): Talon Therapeutics; 2012 [cited 2014 Dec 16]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202497s0001b1.pdf
4. Full prescribing information for Clolar® (clofarabine) injection for intravenous use [PDF onthe Internet]. Cambridge (MA): Genzyme; 2014 [cited 2014 Dec 16]. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/label/2014/021673s0231b1.pdf
5. Faderl S, Thomas DA, O'Brien S, Ravandi F, Garcia-Manero G, Borthakur G., et al. Augmented hyper-CVAD based on dose-intensified vincristine, dexa-methasone, and asparaginase in adult acute lymphoblastic leukemia salvage therapy. Clin Lymphoma Myeloma Leuk 2011; 11: 54-9.
6. Kozlowski P, Astrom M, Ahlberg L., Bernell P, Hulegardh E, Karlsson K., et al. High curability via intensive reinduction chemotherapy and stem cell transplantation in young adults with relapsed acute lymphoblastic leukemia in Sweden 2003-2007. Haematol 2012; 97: 1414-21.
7. Gokbuget N, Stanze D, Beck J., Diedrich H, Horst HA, Huttmann A, et al Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood 2012; 120: 2032-42.
8. Raetz EA, Borowitz MJ, Devidas M, Linda S.B., Hunger SP, Winick NJ, et al. Reinduction platform for children with first marrow relapse of acute lymphoblastic leukemia: A Children's Oncology Group Study. J Clin Oncol 2008; 26: 3971-8.
9. Drugs@FDA [database onthe Internet]. Silver Spring (MD): U.S. Food and Drug Administration [cited 2015 Jan 19]. Drug approval package. Blincyto (blinatumomab) injection. Available from: http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/125557Orig1s000TOC.cfm. Files updated daily.
10. Zugmaier G, Handgretinger R, Locatelli F, Rizzari C, Trippett TM, Borkhardt A, et al. A Phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia [abstract]. In: Proceedings of the 57th ASH Annual Meeting and Exposition; 2013 Dec 5-8; Orlando, FL. Washington (DC): American Society of Hematology; 2013. Abstract nr 70.
11. Topp MS, Gokbuget N, Zugmaier G., Klappers P, Stelljes M, Neumann S., et al. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia. J Clin Oncol 2014; 32: 4134-40.
12. Appelbaum FR, Rosenblum D, Arceci R.J., Carroll WL, Breitfield PP, Forman SJ, et al End points to establish the efficacy of new agents in the treatment of acute leukemia. Blood 2007; 209: 1810-6.
13. Dillman RO, Beauregard JC, Halpern S.E., Clutter M. Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies. J Biol Response Mod 1986; 5: 73-84.
14. Chatenoud L, Ferran C, Legendre C., Thouard I, Merite S, Reuter A., et al. In vivo cell activation following OKT3 administration: systemic cytokine release and modulation by corticosteroids. Transplantation 1990; 49: 697-702.
15. Bioemena E, ten Berge IJ, Surachno J, Wilmink JM. Kinetics of interleukin-6 during OKT3 treatment in renal allograft recipients. Transplantation 1990; 50: 330-1.
16. Parizel PM, Snoeck HW, van den Hauwe L, Boven K, Bosmans J.L., Van-Goethem JW, et al. Cerebral complications of murine monoclonal CD3 antibody (OKT3): CT and MR findings. Am J Neuroradiol 1997; 18: 1935-8.
17. Thaisetthawatkul P, Weinstock A, Kerr S.L., Cohen ME. Muromonab-CD3-induced neurotoxicity: report of two siblings, one of whom had subsequent cyclosporin-induced neurotoxicity. J Child Neurol 2001; 16: 825-31.
18. Zugmaier G, Topp MS, Alekar S, Viardot A., Horst HA, Neumann S, et al. Long-term follow-up of serum immunoglobulin levels in blinatumomab-treated patients with minimal residual disease-positive B-precursor acute lymphoblastic leukemia. Blood Cancer J 2014; 4: 244.
19. Topp MS, Kufer P, Gokbuget N., Goebler M, Klinger M, Neumann S., et al. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lym-phoblastic leukemia patients results in high response rate and prolonged leukemia-free survival. J Clin Oncol 2011; 29: 2493-8.